Genotype-Renal Function Correlation in Type 2 Autosomal Dominant Polycystic Kidney Disease
- 1 May 2003
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 14 (5) , 1164-1174
- https://doi.org/10.1097/01.asn.0000061774.90975.25
Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is a common Mendelian disorder that affects approximately 1 in 1000 live births. Mutations of two genes, PKD1 and PKD2, account for the disease in approximately 80 to 85% and 10 to 15% of the cases, respectively. Significant interfamilial and intrafamilial renal disease variability in ADPKD has been well documented. Locus heterogeneity is a major determinant for interfamilial disease variability (i.e., patients from PKD1-linked families have a significantly earlier onset of ESRD compared with patients from PKD2-linked families). More recently, two studies have suggested that allelic heterogeneity might influence renal disease severity. The current study examined the genotype-renal function correlation in 461 affected individuals from 71 ADPKD families with known PKD2 mutations. Fifty different mutations were identified in these families, spanning between exon 1 and 14 of PKD2. Most (94%) of these mutations were predicted to be inactivating. The renal outcomes of these patients, including the age of onset of end-stage renal disease (ESRD) and chronic renal failure (CRF; defined as creatinine clearance ≤ 50 ml/min, calculated using the Cockroft and Gault formula), were analyzed. Of all the affected individuals clinically assessed, 117 (25.4%) had ESRD, 47 (10.2%) died without ESRD, 65 (14.0%) had CRF, and 232 (50.3%) had neither CRF nor ESRD at the last follow-up. Female patients, compared with male patients, had a later mean age of onset of ESRD (76.0 [95% CI, 73.8 to 78.1] versus 68.1 [95% CI, 66.0 to 70.2] yr) and CRF (72.5 [95% CI, 70.1 to 74.9] versus 63.7 [95% CI, 61.4 to 66.0] yr). Linear regression and renal survival analyses revealed that the location of PKD2 mutations did not influence the age of onset of ESRD. However, patients with splice site mutations appeared to have milder renal disease compared with patients with other mutation types (P < 0.04 by log rank test; adjusted for the gender effect). Considerable renal disease variability was also found among affected individuals with the same PKD2 mutations. This variability can confound the determination of allelic effects and supports the notion that additional genetic and/or environmental factors may modulate the renal disease severity in ADPKD. E-mail: york.pei@uhn.on.caKeywords
This publication has 35 references indexed in Scilit:
- Genetics and Pathogenesis of Polycystic Kidney DiseaseJournal of the American Society of Nephrology, 2002
- A Test for Linkage and Association in General Pedigrees: The Pedigree Disequilibrium TestAmerican Journal of Human Genetics, 2000
- The ACE insertion/deletion polymorphism has no influence on progression of renal function loss in autosomal dominant polycystic kidney diseaseNephrology Dialysis Transplantation, 2000
- Location of mutations within the PKD2 gene influences clinical outcomeKidney International, 2000
- Familial phenotype differences in PKD1Kidney International, 1999
- Comparison of phenotypes of polycystic kidney disease types 1 and 2The Lancet, 1999
- Somatic Inactivation of Pkd2 Results in Polycystic Kidney DiseaseCell, 1998
- Characterization of the Exon Structure of the Polycystic Kidney Disease 2 Gene (PKD2)Genomics, 1997
- A dominant mutation in the Ikaros gene leads to rapid development of leukemia and lymphomaCell, 1995
- Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1The Lancet, 1994